Etoricoxib: Difference between revisions
No edit summary |
|||
| Line 34: | Line 34: | ||
Etoricoxib should not be given to patients with severe hepatic impairment. | Etoricoxib should not be given to patients with severe hepatic impairment. | ||
==Side Effects== | |||
Common side effects include: | |||
*Abdominal pain, nausea and diarrhea. | |||
Serious side effects may include: | |||
*Heart attacks | |||
*Strokes | |||
*Gastrointestinal perforation | |||
*Gastrointestinal bleeding | |||
*Kidney failure | |||
*Anaphylaxis | |||
It is generally accepted that COX-2 inhibitor may cause less gastrotoxicity than that seen with the non-selective inhibition of the traditional NSAIDs. However, reports that upper gastrointestinal perforation, ulceration and bleeds have occurred with etoricoxib treatment and should not be used in patients with active gastrointestinal ulceration or bleeding. | |||
Revision as of 23:52, 28 September 2020
Catergory: Etoricoxib
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Arcoxia Tablet 120 mg | P1S1S3 |
Mechanism of Action
Anti-inflammatory agent, Non-steroidal anti-inflammatory drug (NSAID) Selective COX-2 inhibitor
Dosage
For osteoarthritis
Oral: 30 mg daily once daily, increased to 60 mg once daily if necessary.
For rheumatoid arthritis and ankylosing spondylitis
Oral: 60 mg once daily, increased to 90 mg once daily if necessary.
For gouty arthritis
Oral: 120 mg once daily.
Such higher doses should only be used for acute symptomatic period and for a maximum of 8 days.
For postoperative dental pain
Oral: 90 mg once daily for a maximum of 3 days.
Administration in hepatic impairment
Mild hepatic impairment: 60 mg once daily
Moderate hepatic impairment: 60 mg every other day or 30 mg once daily.
Etoricoxib should not be given to patients with severe hepatic impairment.
Side Effects
Common side effects include:
- Abdominal pain, nausea and diarrhea.
Serious side effects may include:
- Heart attacks
- Strokes
- Gastrointestinal perforation
- Gastrointestinal bleeding
- Kidney failure
- Anaphylaxis
It is generally accepted that COX-2 inhibitor may cause less gastrotoxicity than that seen with the non-selective inhibition of the traditional NSAIDs. However, reports that upper gastrointestinal perforation, ulceration and bleeds have occurred with etoricoxib treatment and should not be used in patients with active gastrointestinal ulceration or bleeding.
